Form 4: CRISPR Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Simeon George, a Director of CRISPR Therapeutics AG, sold 14,514 shares of common stock on October 14, 2026 for $49.63 per share.
Summary
- Option exercise/conversion: acquired 30,000 Common Shares at $14.00 ($420,000) on October 14, 2026; holds 30,000 after (Direct).
- Open-market sale: disposed of 14,514 Common Shares at $49.63 ($720,373) on October 14, 2026; holds 15,486 after (Direct).
- Option exercise/conversion: disposed of 30,000 Stock Option (Right to Buy) on October 14, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $720,373 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Simeon George — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-14 | Option exercise/conversion | Common Shares | 30,000 | $14 | $420.0K | 30,000 |
| 2026-10-14 | Open-market sale | Common Shares | 14,514 | $50 | $720.4K | 15,486 |
| 2026-10-14 | Option exercise/conversion | Stock Option (Right to Buy) | 30,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-14 | Option exercise/conversion (30,000 shares) |
| 2026-10-14 | Open-market sale (14,514 shares) |
| 2026-10-14 | Option exercise/conversion (30,000 shares) |
Keywords
insider transaction, Form 4, CRSP, CRISPR Therapeutics AG, bearish, Simeon George
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.